NZ747693A - Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors - Google Patents

Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors

Info

Publication number
NZ747693A
NZ747693A NZ747693A NZ74769317A NZ747693A NZ 747693 A NZ747693 A NZ 747693A NZ 747693 A NZ747693 A NZ 747693A NZ 74769317 A NZ74769317 A NZ 74769317A NZ 747693 A NZ747693 A NZ 747693A
Authority
NZ
New Zealand
Prior art keywords
derivatives
riboside
nicotinic acid
nicotinamide
ribofuranosyl
Prior art date
Application number
NZ747693A
Other languages
English (en)
Inventor
Troy Rhonemus
Ryan Dellinger
Mark Morris
Aron Erickson
Hadi Cassier
Marie Migaud
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of NZ747693A publication Critical patent/NZ747693A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
NZ747693A 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors NZ747693A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662325264P 2016-04-20 2016-04-20
PCT/US2017/028673 WO2017184885A1 (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors

Publications (1)

Publication Number Publication Date
NZ747693A true NZ747693A (en) 2023-07-28

Family

ID=60088650

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ747693A NZ747693A (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors

Country Status (13)

Country Link
US (1) US10183036B2 (OSRAM)
EP (1) EP3445359B8 (OSRAM)
JP (3) JP7089480B2 (OSRAM)
KR (1) KR20190008246A (OSRAM)
CN (1) CN109640984A (OSRAM)
AU (2) AU2017254657A1 (OSRAM)
BR (1) BR112018071573A2 (OSRAM)
CA (1) CA3021571C (OSRAM)
ES (1) ES2948968T3 (OSRAM)
MX (1) MX393076B (OSRAM)
NZ (1) NZ747693A (OSRAM)
WO (1) WO2017184885A1 (OSRAM)
ZA (1) ZA201807736B (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011788A1 (en) 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
EP3331894B1 (en) 2015-08-05 2021-02-17 Metro International Biotech, LLC Nicotinamide mononucleotide derivatives and their uses
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
NZ803738A (en) 2016-11-11 2024-05-31 Chromadex Inc Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
JP7136795B2 (ja) 2016-11-29 2022-09-13 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 母体の健康および/または子の健康を向上させるためのnad前駆体の使用
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
WO2018191771A1 (en) * 2017-04-18 2018-10-25 Victor Chang Cardiac Research Institute Detection and treatment of congenital malformations
US11286274B2 (en) 2017-06-19 2022-03-29 Mitopower Llc Nicotinamide riboside derivatives and their uses
WO2019152416A1 (en) * 2018-01-30 2019-08-08 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
WO2019226755A1 (en) * 2018-05-22 2019-11-28 Jumpstart Fertility Pty Ltd Amino acid salts of nicotinic acid ribosides as anti-aging agents
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
BR112021016432A2 (pt) 2019-02-21 2021-11-09 Chromadex Inc Composição que compreende prills de cera, processo para produzir prills de cera, composição nutricional, alimento, bebida ou suplemento alimentar que compreende prills de cera, e composição que compreende microesferas encapsuladas
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
EP3980027A1 (en) * 2019-06-05 2022-04-13 Société des Produits Nestlé S.A. Reduced nicotinamideribosides for the treatment/prevention of liver disease
BR112021021690A2 (pt) * 2019-06-05 2022-02-15 Nestle Sa Ribosídeos de nicotinamida reduzidos para tratamento/prevenção de doenças do músculo esquelético
EP3980026B1 (en) * 2019-06-05 2024-07-31 Société des Produits Nestlé S.A. Reduced nicotinamide ribosides for treating or preventing kidney disease
CN110973260A (zh) * 2019-12-11 2020-04-10 杨力 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用
EP4076458A1 (en) 2019-12-19 2022-10-26 Leibniz-lnstitut Für Altersforschung Nad-precursors and dietary restriction for treating age-related medical conditions
EP4117677A1 (en) * 2020-03-09 2023-01-18 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions
WO2021180739A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of viral and bacterial infections
EP4117678A1 (en) * 2020-03-09 2023-01-18 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions
US20230138327A1 (en) * 2020-03-09 2023-05-04 Societe Des Produits Nestle S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions
CN114561342B (zh) * 2020-11-27 2024-12-20 西安交通大学医学院第一附属医院 Nad信号通路激动剂在体外胚胎培养中的应用
CN115669929A (zh) * 2021-01-15 2023-02-03 江苏恒正合生命科学有限公司 辅助改善记忆的功能性食品其制备方法
CN118201621A (zh) * 2021-05-05 2024-06-14 雀巢产品有限公司 使用narh和nr的组合来产生细胞内烟酰胺腺嘌呤二核苷酸(nad+)的组合物和方法
KR20240020716A (ko) 2021-05-27 2024-02-15 메트로 인터내셔널 바이오테크 엘엘씨 니코틴산 모노뉴클레오타이드 및 이의 에스터의 결정질 고체 및 제조 및 사용 방법
EP4313067A4 (en) * 2021-06-18 2024-12-18 Mitopower LLC TREATMENT OF IMMUNITY-RELATED DISORDERS, RENAL DISORDERS, LIVER DISORDERS, HEMOLYTIC DISORDERS AND OXIDATIVE STRESS-RELATED DISORDERS USING NRH, NARH AND THEIR REDUCED DERIVATIVES
EP4422644A4 (en) * 2021-10-27 2025-08-27 Elysium Health Inc METHODS OF TREATING MENOPAUSAL SYNDROMES
JP7111878B1 (ja) 2021-10-27 2022-08-02 旭化成ファーマ株式会社 ニコチンアミドモノヌクレオチドの製造方法
WO2023150072A1 (en) 2022-02-01 2023-08-10 Sinclair David A Compositions and methods for the preservation of plant matter
WO2023150667A2 (en) * 2022-02-04 2023-08-10 Elysium Health Inc. Ribose linkers and conjugates thereof
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022680B2 (en) 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7927859B2 (en) * 2003-08-22 2011-04-19 Rice University High molar succinate yield bacteria by increasing the intracellular NADH availability
EP1723227A4 (en) 2004-02-10 2007-09-19 Dartmouth College NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
EP3006040B1 (en) 2004-06-04 2017-11-22 Washington University Methods and compositions for treating neuropathies
ES2670927T3 (es) * 2005-11-18 2018-06-04 Cornell Research Foundation, Inc. Composiciones de nicotinoil ribósido y métodos de uso
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
CA2928656C (en) 2013-10-30 2020-07-28 ChromaDex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
CN106715455A (zh) * 2014-06-06 2017-05-24 葛兰素史密斯克莱知识产权(第2 号)有限公司 烟酰胺核苷类似物及其药物组合物和用途
EP3271370B1 (en) * 2015-03-16 2023-06-21 Chromadex Inc. Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof
WO2017011788A1 (en) 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
EP3331894B1 (en) 2015-08-05 2021-02-17 Metro International Biotech, LLC Nicotinamide mononucleotide derivatives and their uses
CA3021022C (en) * 2016-04-14 2024-04-23 ChromaDex Inc. Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula

Also Published As

Publication number Publication date
ES2948968T3 (es) 2023-09-22
ZA201807736B (en) 2020-05-27
BR112018071573A2 (pt) 2019-02-12
CA3021571C (en) 2023-01-03
CN109640984A (zh) 2019-04-16
WO2017184885A1 (en) 2017-10-26
JP7493007B2 (ja) 2024-05-30
JP2023002685A (ja) 2023-01-10
MX393076B (es) 2025-03-24
US10183036B2 (en) 2019-01-22
AU2022221384C1 (en) 2023-08-03
JP7089480B2 (ja) 2022-06-22
AU2022221384A1 (en) 2022-09-22
MX2018012849A (es) 2019-08-29
JP2019514874A (ja) 2019-06-06
CA3021571A1 (en) 2017-10-26
JP2021176871A (ja) 2021-11-11
US20170304338A1 (en) 2017-10-26
AU2022221384B2 (en) 2023-03-23
EP3445359A1 (en) 2019-02-27
EP3445359A4 (en) 2019-12-25
AU2017254657A1 (en) 2018-11-15
KR20190008246A (ko) 2019-01-23
EP3445359C0 (en) 2023-06-07
WO2017184885A8 (en) 2023-08-24
EP3445359B1 (en) 2023-06-07
EP3445359B8 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
NZ747693A (en) Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors
EA201890435A1 (ru) Производные никотинамидмононуклеотида и их применение
WO2020131578A3 (en) Nicotinyl riboside compounds and their uses
ZA202106912B (en) Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations
NZ739339A (en) Apoptosis signal-regulating kinase inhibitor
ATE547098T1 (de) Orale formulierung mit vorteilhaften kardiovaskulären wirkungen und berberin-gehalt
WO2010123591A3 (en) Small molecule inhibitors of nads, namnat, and nmnat
WO2014078778A3 (en) Antiviral azasugar-containing nucleosides
TW200607804A (en) Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
PH12014501134A1 (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
MY170437A (en) Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
MX352927B (es) Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa.
MX2015008837A (es) Composiciones parenterales estables de dnj.
Endo et al. Synthesis of non-prenyl analogues of baccharin as selective and potent inhibitors for aldo-keto reductase 1C3
MX2010005198A (es) Composiciones liquidas que comprenden valsartan.
DOP2010000342A (es) Compuestos conteniendo nitrogeno triciclico y sus usos como antibacteriales
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
CY1108314T1 (el) Σκευασμα για στοματικη χορηγηση εχοντας μια δραση που προαγει την υγεια επι του καρδιαγγειακου συστηματος
AU2017241626A1 (en) Viable cell compositions, and methods related to same
WO2006072809A8 (en) Formulations that optimize intracellular concentration of nicotinamide adenine (nad+) and methods of use to protect cells and treat diseases and conditions
WO2024259359A3 (en) Nicotinamide riboside and derivatives thereof in intravenous formulations and methods of use thereof
BR112021024663A2 (pt) Composições e métodos que usam trigonelina para produzir nad+ intracelular
WO2011103586A3 (en) Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine
EP1868613A4 (en) POLYMORPHOS OF 3-O- (3 ', 3'-DIMETHYLSUCCINYL) BETULINIC DI-N-METHYL-D-GLUCAMINE
MX2025001193A (es) Derivados de androstano con actividad como estimuladores puros o predominantemente puros de serca2a para el tratamiento de la insuficiencia cardiaca

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 APR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 20 APR 2026 BY COMPUTER PACKAGES INC

Effective date: 20250417